Echevarria v. AstraZeneca, LP

133 F. Supp. 3d 372, 2015 WL 5719809, 2015 U.S. Dist. LEXIS 134988
CourtDistrict Court, D. Puerto Rico
DecidedSeptember 30, 2015
DocketCivil No. 13-1160 (PAD)
StatusPublished
Cited by12 cases

This text of 133 F. Supp. 3d 372 (Echevarria v. AstraZeneca, LP) is published on Counsel Stack Legal Research, covering District Court, D. Puerto Rico primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Echevarria v. AstraZeneca, LP, 133 F. Supp. 3d 372, 2015 WL 5719809, 2015 U.S. Dist. LEXIS 134988 (prd 2015).

Opinion

OPINION AND ORDER

DELGADO-HERNÁNDEZ, District Judge.

Plaintiff Taymari Delgado-Echevarria initiated this action against her former employer, AstraZeneca Pharmaceutical .LP, complaining of age and disability discrimination, hostile work environment, interference with a protected leave of absence, retaliation, tortious conduct, and unjust discharge under various federal and Puer-to Rico statutes.1 Before the court is As-traZeneca’s Motion for Summary Judgment (Docket No. 97). For the reasons explained below, the motion is GRANTED and the case DISMISSED.

I. BACKGROUND

Plaintiff alleges that after years of impeccable employment history with AstraZ-eneca, she disclosed to her immediate supervisor some medical problems to justify days off for treatment. Then, she claims,. the supervisor engaged in a pattern of intense harassment and adverse employment actions in an attempt to fabricate a negative employment record and force her resignation. The pattern exacerbated her conditions to the point where she had to apply for a disability leave of absence, and AstraZeneca granted the leave but refused to authorize an extension, instead terminating her employment without affording her reasonable accommodation (Docket No. 1 at ¶¶ 16-21, 30, 62). AstraZeneca [382]*382denied liability, and following discovery moved for summary judgment (Docket No. 96). Plaintiff opposed AstraZeneca’s motion (Docket No. 114), AstraZeneca replied (Docket No. 123) and plaintiff surreplied (Docket No. 129).2

II. STANDARD OF REVIEW

Summary judgment is appropriate when “the pleadings, depositions, answers to interrogatories and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to judgment as a matter of law.” Fed.R.Civ.P. 56(c). The purpose of summary judgment is to pierce the pleadings and assess the proof in order to see whether there is need for trial. Mesnick v. General Electric Co., 950 F.2d 816, 822 (1st Cir.1991).

The party moving for summary judgment bears the initial responsibility of demonstrating the absence of a genuine issue of material fact. Celotex Corp. v. Catrett, 477 U.S. 317, 323, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). A factual dispute is “genuine” if it could be resolved in favor of either party. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 249, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). It is “material” if it potentially affects the outcome of the case in light of applicable law. Calero-Cerezo v. U.S. Dep’t of Justice, 355 F.3d 6, 19 (1st Cir.2004). As to issues on which the nonmovant has the burden of proof, the movant need to no more than aver absence of evidence to support the non-moving party’s case. Celotex Corp., 477 U.S. at 325, 106 S.Ct. 2548; Mottolo v. Fireman’s Fund Ins. Co., 43 F.3d 723, 725 (1st Cir.1995).

Once the moving party has satisfied this requirement, the nonmoving party has the burden of presenting facts that demonstrate a genuine issue of material fact for trial. LeBlanc v. Great American Ins. Co., 6 F.3d 836, 841 (1st Cir.1993). All reasonable factual inferences must be drawn in favor of the party against whom summary judgment is sought. Shafmaster v. U.S., 707 F.3d 130, 135 (1st Cir.2013).

To resist summary judgment, the nonmovant must do more than show some metaphysical doubt as to a material fact. Matsushita Elec. Inds. Co., Ltd. v. Zenith Radio Corp., 475 U.S. 574, 586, 106 S.Ct. 1348, 89 L.Ed.2d 538 (1986). Conclusory allegations, empty rhetoric, unsupported speculation, or evidence which, in the aggregate, is less than significantly probative will not suffice to ward off a properly supported motion for summary judgment. Nieves-Romero v. U.S., 715 F.3d 375, 378 (1st Cir.2013). Careful record review reflects absence of genuine dispute as to the facts identified in the section that follows. Based on those facts, AstraZeneca is entitled to judgment as a matter of law.

III. FINDINGS OF FACT3

A. The Parties

AstraZeneca is in the business of developing, producing, manufacturing and mar[383]*383keting prescription medications. See Docket No. 96, Exh. 1 “Defendants’ Statement of Uncontested Facts in Support of Motion for Summary Judgment” (“SUMF”) at ¶ 1. During the relevant period, its Regional Sales Director for Puerto Rico was Elsa Saavedra. SUMF at ¶ 11.

Plaintiff was employed by AstraZeneca as a Pharmaceutical Sales Specialist — a sales representative — -in 2001. SUMF at ¶ 8. She was responsible for management of a sales territory and her primary duties included sales and customer service. SUMF at ¶ 9. In 2009 she was promoted to a sales representative position in the newly created Hospital Division. SUMF at ¶ 16. Her duties did not change but the products she was responsible for did. SUMF at ¶ 17.4 In the new position, she was assigned a hospital territory called “Hospital CV East,” covering various hospitals in the municipalities of Caguas, Cayey, Aibonito, Juncos, Las Piedras, Humacao and Fajar-do. SUMF at ¶ 16. She was supervised by AstraZeneca’s Executive District Manager, Maribel Martinez, who in turn, reported to Saavedra. SUMF at ¶ 18.

B. Performance Evaluations

Sales representatives are subject to midyear and annual evaluations, and monitored by way of a “Field Coaching Form.”5 SUMF at ¶¶ 26, 28. The Form is prepared by the representative’s superiors to record the representative’s performance and presentation during field rides (e.g. visits to customers). SUMF at ¶ 29. Field rides are conducted to evaluate the representatives’ strengths and weaknesses. Id. The information recorded is made part of the representative’s annual performance evaluation. SUMF at ¶ 32.

C. Plaintiff’s performance

In the Form corresponding to the April 12, 2010 field ride, Martinez recorded that plaintiff, partially met expectations in four (4) out of the five (5) areas. SUMF at ¶ 33. She stated that plaintiffs “focus should be to the top customers to the specific objective and the simplicity of the conversation so the features and benefits of our portfolio begins to be the solution for the customers.” Id. Further, she pointed out that plaintiff had to “plan for the objective to be clear and simple, follow up on the rearrangement of routing so you impact those top customers with the right reach and frequency, important to allocate the resources since the beginning of the month so you are giving the tops the most [sic] of the resourc [sic].” Id. The Forms corresponding to the field rides of May, June, and July 2010, reflect plaintiffs generally meeting expectations.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Roy Bingham v. Giant Eagle, Inc.
W.D. Pennsylvania, 2025
Rivera v. Altranais Home Care LLC
D. Massachusetts, 2022
O'Rourke v. Tiffany and Company
D. Rhode Island, 2020
Olson v. Chao
D. Massachusetts, 2019
Pizarro-Correa v. Puerto Rico Internal Revenue Department
267 F. Supp. 3d 369 (D. Puerto Rico, 2017)
Vargas-Medina v. Ortho Biologics, LLC
247 F. Supp. 3d 169 (D. Puerto Rico, 2017)
Reyes-Feliciano v. Marshalls
159 F. Supp. 3d 297 (D. Puerto Rico, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
133 F. Supp. 3d 372, 2015 WL 5719809, 2015 U.S. Dist. LEXIS 134988, Counsel Stack Legal Research, https://law.counselstack.com/opinion/echevarria-v-astrazeneca-lp-prd-2015.